FDA Approves Apalutamide (Erleada); the first treatment for non-metastatic castration-resistant prostate cancer (READ MORE HERE).
To address the challenges of resistance to..
Maria Karlou, PhD:
University of Athens
Christopher Logothetis, MD
Prostate cancer diagnosis and precision medicine decisions..
Rajan Kulkarni, MD, PhD:
David Geffen School of Medicine at UCLA
Matthew Rettig, MD, Dino Di Carlo, PhD
Utilizing Vortex Chip for Enumeration and Determination of Single-Cell Heterogeneity of Circulating Tumor Cells in Prostate Cancer
T cells are immune cells with a..
Haydn Kissick, PhD:
The Emory Vaccine Center and the Department of Urology, Emory University
Martin Sanda, MD, Rafi Ahmed, PhD
Vaccination against Patient Specific Coding Mutations to Treat Prostate Cancer
The poor solubility and bioavailability of many..
Charalambos Kaittanis, PhD:
Memorial Sloan-Kettering Cancer Center
Jan Grimm, MD, PhD, Steven M. Larson, MD
Overcoming Drug Resistance in Advanced Prostate Cancer with Multifunctional Nanosponges
Biomarkers of Response to Treatment with XL184..
Medical Director of Biorepository and Translational Pathology
Cedars-Sinai Medical Center
Lifestyle, guidelines, and etools to improve prostate..
Stacey Kenfield, ScD:
University of California, San Francisco
June Chan, ScD
Investigating the biological significance of novel recurrent..
Kalpana Kannan, PhD:
Baylor College of Medicine
Laising Yen, PhD and Michael Ittman, MD, PhD
Certain oncogenic molecules in prostate cancer cells..
Theodoros Karantanos, MD:
MD Anderson Cancer Center
Timothy Thompson, PhD and Christopher Logothetis, MD
The role of aerobic glycolysis in the development of castrate resistant prostate cancer
New therapeutic targets and prognostic biomarkers for..
Vishal Kothari, PhD:
University of Michigan
Arul Chinnaiyan, MD, PhD; Felix Feng, MD
Investigating DNAPK as a Therapeutic Target and a Prognostic Biomarker in Castration-Resistant Prostate Cancer
The emergence of treatment-resistant prostate cancer (CRPC)..
Won Kim, MD:
Charles Ryan, MD; Eric Small, MD
Dissecting Variant Androgen Signaling Phenotypes to Guide Treatment Selection in Abiraterone Acetate and Enzalutamide-Resistant Prostate Cancer
Executive Vice President
Koch Industries, Inc.
Philip Kantoff, MD received his undergraduate degree..
Chairman, Global Treatment Sciences Network
Prostate Cancer Foundation
Chairman of Medicine
Memorial Sloan Kettering Cancer Center